20210901 Extracellular and nuclear PD-L1 in modulating cancer immunotherapy
发布时间:2021-08-25  来源:  阅读次数:

Xiong, W., Gao, Y., Wei, W.*, and Zhang, J.* (2021). Extracellular and nuclear PD-L1 in modulating cancer immunotherapy. Trends Cancer 7, 837-846.(张金方)



Although targeting programmed death 1/programmed death ligand 1 (PD-1/PD-L1) has achieved durable responses and disease remission in patients with certain cancers, relatively low response rates and emerging resistance limit its clinical application. Hence, a more thorough understanding of regulatory mechanisms of the PD-1/PD-L1 axis is vital for developing combined therapeutic strategies to overcome hurdles of PD-1/PD-L1 blockade. Increasing evidence has demonstrated that PD-L1 can be secreted into the extracellular space or translocated into the nucleus, which also plays a critical role in regulating cancer immune evasion, tumorigenesis, and immunotherapy. In this review, we summarize these emerging roles of extracellular and nuclear PD-L1 and discuss future research directions and potential opportunities in translational medicine.







地 址:湖北省武汉市武昌区东湖路115号 邮政编码:430071 电 话:027-68750205  邮 箱:mri@whu.edu.cn

CopyRight ? 2016  版权所有:武汉大学a日本亚洲欧洲免费天堂